Clinical features and prognostic factors of patients with COVID-19 in Henan Province, China

Zhang, Qianqian; Wang, Zheng; Lv, Yanping; Zhao, Jin; Dang, Qiang; Xu, Dong; Zhao, Dongxiang; Liu, Haiyang; Wang, Ziqi; Zhao, Xingru; Xu, Zhiwei

doi:10.1007/s13577-021-00499-y

Cited by 19 publications

(16 citation statements)

References 30 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The World Health Organization (WHO) categorizes the clinical severity of COVID-19 as asymptomatic, mild, moderate (non-severe pneumonia), severe (severe pneumonia), and critical disease [6]. In cases of COVID-19 pneumonia, most of the chest radiographs (CXR) have shown ground-glass opacification (GGO), consolidation, or combination with bilateral lower lobe involvement [7].…”

Section: Introductionmentioning

confidence: 99%

Comparative Study of Early Impacts of Post-COVID-19 Pneumonia on Clinical Manifestations, Pulmonary Function, and Chest Radiographs

et al. 2022

View full text Add to dashboard Cite

Background and Objectives: Scant data regarding early post-COVID-19 effects are available, especially in younger people. Therefore, the objective of this study was to explore the early clinical impacts of post-COVID-19 pneumonia, comparing severe and non-severe patients. Materials and Methods: A cross-sectional study was conducted in adult patients admitted with COVID-19 pneumonia from April to May 2021. Demographic data, symptoms and signs, quality of life, Hospital Anxiety and Depression Scale (HADS), chest radiograph (CXR), pulmonary function tests (spirometry, impulse oscillometry), fractional exhaled nitric oxide (FeNO), and exercise capacity were assessed one month after hospital discharge. Twenty-five healthy control subjects that were age- and gender-matched were recruited for comparisons. Results: One hundred and five patients, with a mean age of 35.6 ± 15.8 years and 54 (51.4%) males, participated and were categorized into the non-severe pneumonia (N = 68) and severe pneumonia groups (N = 37). At a one-month follow-up visit (the time from the onset of the disease symptoms = 45.4 ± 5.9 days), the severe group had more cough, fatigue, and skin rash with higher dyspnea scale, more residual CXR lesions, and lower quality of life scores. Forced vital capacity (FVC) was lower in the severe group (88.3% of predicted value) and non-severe group (94.6% of predicted value) than in the healthy controls (p = 0.001). The six-minute walk distance was significantly lower in the non-severe group, at 79.2 m, and in the severe group, at 103.8 m, than in the healthy control subjects (p < 0.001). Conclusions: Adult patients with COVID-19, especially those with clinically severe pneumonia, still had residual symptoms and chest radiographic abnormalities, together with poorer quality of life and lower exercise capacity, one month after hospital discharge.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparative Study of Early Impacts of Post-COVID-19 Pneumonia on Clinical Manifestations, Pulmonary Function, and Chest Radiographs

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Manifestations of COVID‐19 range from mild upper respiratory illness to severe bilateral pneumonia, acute respiratory distress syndrome (ARDS), disseminated thrombosis, multi‐organ failure, and death. 1 , 2 , 3 However, not all infected individuals develop a clinically significant disease. Early identification of healthy virus carriers has been the cornerstone of campaigns to prevent infection spread since Germany's first report which demonstrated their potential contagiousness.…”

Section: Introductionmentioning

confidence: 99%

A bird's eye view on the role of dendritic cells in SARS‐CoV‐2 infection: Perspectives for immune‐based vaccines

Galati

Zanotta

Capitelli

et al. 2021

Allergy

View full text Add to dashboard Cite

Coronavirus disease‐19 (COVID‐19) is a complex disorder caused by the pandemic diffusion of a novel coronavirus named SARS‐CoV‐2. Clinical manifestations vary from silent infection to severe pneumonia, disseminated thrombosis, multi‐organ failure, and death. COVID‐19 pathogenesis is still not fully elucidated, while increasing evidence suggests that disease phenotypes are strongly related to the virus‐induced immune system's dysregulation. Indeed, when the virus‐host cross talk is out of control, the occurrence of an aberrant systemic inflammatory reaction, named “cytokine storm,” leads to a detrimental impairment of the adaptive immune response. Dendritic cells (DCs) are the most potent antigen‐presenting cells able to support innate immune and promote adaptive responses. Besides, DCs play a key role in the anti‐viral defense. The aim of this review is to focus on DC involvement in SARS‐CoV‐2 infection to better understand pathogenesis and clinical behavior of COVID‐19 and explore potential implications for immune‐based therapy strategies.

show abstract

“…results shown in Fig 4 indicate that ARDS (OR = 39.59, 95% CI: 19.99-78.41; I 2 = 48.7%)[11, 13-15, 17, 20, 22, 24, 26, 44], shock (OR = 21.50, 95% CI: 10.49-44.06; I 2 = 27.4%)[11,13,15,17,20,22,24,43,44,51] and AKI (OR = 8.84, 95% CI: 4.34-18.00; I 2 = 40.7%)[11, 13-15, 18, 20, 24, 26, 44, 51] which are potential life-threatening conditions, were clearly responsible for the ICU admissions. Additionally, some other complications like DIC (OR = 29.75, 95%…”

mentioning

confidence: 99%

“…Other significant outcomes included coronary heart disease (OR: 2.87, 95% CI: 2.22-3.71; I 2 = 59.9%)[11-15, 17, 20, 22-38, 41-45, 47, 49-51], malignancy (OR = 2.60, 95% CI: 2.00-3.40; I 2 = 11.9%)[11, 13, 15, 17, 20, 22-26, 28, 30-32, 34-38, 41, 43], cerebrovascular disease (OR = 2.47, 95% CI: 1.54-3.97; I 2 = 28.4%)[11,13,14,20,22,24,25,34,38,40,42,44,50,51], hypertension (OR = 2.42, 95% CI: 2.03-2.88; I 2 = 67.9%)[11-18, 20, 22-51], diabetes…”

mentioning

confidence: 99%

See 1 more Smart Citation

Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

Objective We aimed to systematically identify the possible risk factors responsible for severe cases. Methods We searched PubMed, Embase, Web of science and Cochrane Library for epidemiological studies of confirmed COVID-19, which include information about clinical characteristics and severity of patients’ disease. We analyzed the potential associations between clinical characteristics and severe cases. Results We identified a total of 41 eligible studies including 21060 patients with COVID-19. Severe cases were potentially associated with advanced age (Standard Mean Difference (SMD) = 1.73, 95% CI: 1.34–2.12), male gender (Odds Ratio (OR) = 1.51, 95% CI:1.33–1.71), obesity (OR = 1.89, 95% CI: 1.44–2.46), history of smoking (OR = 1.40, 95% CI:1.06–1.85), hypertension (OR = 2.42, 95% CI: 2.03–2.88), diabetes (OR = 2.40, 95% CI: 1.98–2.91), coronary heart disease (OR: 2.87, 95% CI: 2.22–3.71), chronic kidney disease (CKD) (OR = 2.97, 95% CI: 1.63–5.41), cerebrovascular disease (OR = 2.47, 95% CI: 1.54–3.97), chronic obstructive pulmonary disease (COPD) (OR = 2.88, 95% CI: 1.89–4.38), malignancy (OR = 2.60, 95% CI: 2.00–3.40), and chronic liver disease (OR = 1.51, 95% CI: 1.06–2.17). Acute respiratory distress syndrome (ARDS) (OR = 39.59, 95% CI: 19.99–78.41), shock (OR = 21.50, 95% CI: 10.49–44.06) and acute kidney injury (AKI) (OR = 8.84, 95% CI: 4.34–18.00) were most likely to prevent recovery. In summary, patients with severe conditions had a higher rate of comorbidities and complications than patients with non-severe conditions. Conclusion Patients who were male, with advanced age, obesity, a history of smoking, hypertension, diabetes, malignancy, coronary heart disease, hypertension, chronic liver disease, COPD, or CKD are more likely to develop severe COVID-19 symptoms. ARDS, shock and AKI were thought to be the main hinderances to recovery.

show abstract

Clinical features and prognostic factors of patients with COVID-19 in Henan Province, China

Cited by 19 publications

References 30 publications

Comparative Study of Early Impacts of Post-COVID-19 Pneumonia on Clinical Manifestations, Pulmonary Function, and Chest Radiographs

Comparative Study of Early Impacts of Post-COVID-19 Pneumonia on Clinical Manifestations, Pulmonary Function, and Chest Radiographs

A bird's eye view on the role of dendritic cells in SARS‐CoV‐2 infection: Perspectives for immune‐based vaccines

Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis

Contact Info

Product

Resources

About